Retraction Watch has been a great resource for those of us who have been following research misconduct. They widely cover and conduct research on retractions, corrections, and other developments in this space. Unfortunately, there’s been plenty to write about even just within the stem cell and cell therapy arena, which is my primary interest. Think […]
Many of us first became aware of Vivek Ramaswamy as a Republican candidate for President. He was most well-known before that as a biotech leader. Given that biotech background, I decided to learn more about him. Surprisingly, his biomedical efforts may have started with embryonic stem cells. That caught my attention. This was way back
Vivek Ramaswamy & his surprising stem cell start Read More »
Several groups including Viviane Tabar who is a founding scientist at BlueRock Therapeutics are moving forward on potential cell therapies for Parkinson’s Disease. BlueRock just released some new data that’s worth a look. Check out the new BlueRock poster. In today’s post, I briefly discuss the new data. I also go into the larger context
Small positive step for BlueRock Therapeutics Stem Cell Therapy for Parkinson’s Read More »
Many avenues are being pursued to get stem cell therapy to the clinic for eye conditions. These different approaches employ a variety of stem cell types. In some cases, such as with iPS cells, the stem cells themselves are not transplanted. Instead, the iPS cells are used to make differentiated eye cells, such as RPE
Weekly reads: stem cell therapy for eyes research, DMD, cheating death, cancer sensors Read More »
Early during my postdoc I was primarily interested in the role of Myc genes both in cancer and in stem cells, work that later included embryonic stem cells. These cells are often called ES cells. At first I first started studying N-Myc in neural stem cells using a conditional knockout approach. However, soon after I was
Weekly reads: embryonic stem cells, Parkinson’s, Alzheimer’s Read More »
It feels like I’ve been writing about the Florida clinic US Stem Cell for a very long time. The FDA has been aware of them for about as long. It was only after reports of patient injuries that the FDA at last took action on US Stem Cell and its subsidiary US Stem Cell Clinic. Several
Did US Stem Cell Clinic defy FDA injunction? New injured patient suit sparks questions Read More »
Australian biotech Mesoblast has had a rollercoaster ride working toward FDA approval of its mesenchymal cell therapy product remestemcel-L. They are seeking approval for use in patients with graft-versus-host disease (GvHD). More specifically, it is intended for pediatric patients with steroid-refractory acute graft versus host disease, or SR-aGVHD. This is a serious condition and new treatment
Hoping for approval, Mesoblast says FDA wants new remestemcel-L trial Read More »
It’s great finding stem cell videos on YouTube that are either excellent research talks or provide important information. I recently found one such video by Shiri Gur-Cohen, which I included below. Interesting data there and Shiri is such a compelling speaker. She also won The Niche image contest one year with a cool microscopy pic
Weekly stem cell reads: Google Bard AI issues, fat ball reprogramming, BrainStorm on ALS Read More »
From the beginning of the pandemic, I have been mostly skeptical about the idea of cell therapy for COVID including stem cell therapies. However, at the same time, I’ve closely followed the data, especially up until 2022. Now having just had a nasty bout with COVID myself for the first time this summer, I recently
Update on stem cells & cell therapy for COVID trials Read More »
Where do things stand with the investigative approach of stem cells for diabetes? 33% of Type 1 Diabetes Patients Insulin-Free With Stem Cells, Medscape. Not the best headline given the few number of participants here. If your study has only two subjects and one responds, someone is going to say, “50% of people had a
Weekly reads: Vertex stem cells for diabetes update, new CRISPR , immortality Read More »